Polyphor AG (POLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Polyphor AG (POLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH137787D
  • |
  • Pages: 29
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Polyphor AG (Polyphor) is a clinical stage biopharmaceutical company that discovers and develops antibiotics and other specialty pharma products for severe or life-threatening diseases. The company offers hematopoietic stem cells for multiple myeloma patients, Pseudomonas infections and protease inhibitors for chronic obstructive pulmonary disease, alpha-1-antitrypsin deficiency, cystic fibrosis and lung diseases, among others. It develops various technology platforms which include MacroFinder and PEMfinder that are used to discover the potent and selective modulators of protein-protein interactions. It also develops proprietary macrocycle technology platform for pharma companies. Polyphor is headquartered in Allschwil, Switzerland.

Polyphor AG (POLN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Polyphor AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Polyphor AG, Medical Devices Deals, 2012 to YTD 2018 9

Polyphor AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Polyphor AG, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Polyphor Raises USD7 Million in Financing 11

Partnerships 12

Polyphor Enters into Licensing Agreement with PARI Pharma 12

Polyphor Enters into Research Agreement with Taisho Pharma 13

Licensing Agreements 14

Santhera Pharma Enters into Licensing Agreement with Polyphor 14

Polyphor Extends Licensing Agreement with Boehringer Ingelheim 15

Gilead Sciences Enters Into Licensing Agreement With Polyphor 16

Equity Offering 17

Polyphor Raises USD167.4 Million in IPO of Shares 17

Polyphor Raises USD10 Million in Private Financing 18

Polyphor AG-Key Competitors 19

Polyphor AG-Key Employees 20

Polyphor AG-Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Financial Announcements 22

Sep 06, 2018: Polyphor reports financial results for the first half 2018 22

Corporate Communications 24

May 24, 2017: Kalina Scott appointed new CFO of Polyphor 24

Government and Public Interest 25

Jan 23, 2018: Polyphor: Global No. 2 in the 2018 Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation 25

Product News 26

07/18/2017: Polyphor achieves ahead of schedule first milestone from Wellcome Trust for the development of novel antibiotics against Gram-negative multidrug-resistant pathogens 26

02/09/2017: Polyphor Receives CHF 2.3 Million Award from Wellcome Trust to Accelerate the Development of a Novel Antibiotic Drug Class 27

Other Significant Developments 28

Apr 13, 2018: Polyphor successfully completes Wellcome Trust collaboration for development of novel antibiotics against multi-drug resistant Gram-negative pathogens 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29

List of Figures

Polyphor AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Polyphor AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Polyphor AG, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Polyphor AG, Pharmaceuticals & Healthcare, Key Facts 2

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Polyphor AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Polyphor AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Polyphor AG, Deals By Therapy Area, 2012 to YTD 2018 8

Polyphor AG, Medical Devices Deals, 2012 to YTD 2018 9

Polyphor AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Polyphor Raises USD7 Million in Financing 11

Polyphor Enters into Licensing Agreement with PARI Pharma 12

Polyphor Enters into Research Agreement with Taisho Pharma 13

Santhera Pharma Enters into Licensing Agreement with Polyphor 14

Polyphor Extends Licensing Agreement with Boehringer Ingelheim 15

Gilead Sciences Enters Into Licensing Agreement With Polyphor 16

Polyphor Raises USD167.4 Million in IPO of Shares 17

Polyphor Raises USD10 Million in Private Financing 18

Polyphor AG, Key Competitors 19

Polyphor AG, Key Employees 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Polyphor AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17835
Site License
USD 500 INR 35670
Corporate User License
USD 750 INR 53505

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com